Sign up to save your podcasts
Or
Share Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView’s “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don’t miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provide new hope for many patients, including those with multiple myeloma, with limited treatment options. Multiple new indications for CAR T-cell therapies have been approved by the FDA already this year, and new research may expand treatment options for patients with heavily pretreated disease or those receiving earlier lines of treatment. With these new therapeutic opportunities, questions arise regarding best practices for using CAR T-cell therapy in the clinic. Check out PeerView’s “Seminars and Tumor Board” program featuring the latest research and expert guidance on the role of CAR T-cell therapy in modern hematologic cancer care. Gain a thorough understanding of the latest efficacy and safety data on these therapies, and learn how to manage the practical aspects of implementing these therapies in the care of patients with hematologic malignancies. With patient cases drawn from practice, our faculty will guide participants through important clinical considerations, including referral of patients to specialized centers, coordination of care, and detecting and managing distinctive CAR T-cell therapy–related adverse events such as cytokine release syndrome (CRS) and immune effector cell neurotoxicity syndrome (ICANS). Don’t miss this opportunity to learn more about the timely, safe, and efficacious use of CAR T-cell therapy. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, mechanisms of action, key efficacy/safety evidence, and expanding clinical roles of current and emerging CAR T-cell therapies for patients with hematologic malignancies; Develop strategies to optimize the delivery of CAR T-cell therapy among patients with hematologic malignancies, including considerations for appropriate patient selection, referral to and care coordination with specialized centers, clinical trial enrollment, and pre-/post-treatment care and support; Employ proactive strategies and best practices to monitor for and manage key toxicities associated with CAR T-cell therapy in patients with hematologic malignancies, including cytokine release syndrome and neurotoxicity.
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
JAMA Editors' Summary
129 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
6 Listeners
Lung Cancer Update
31 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
5 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
318 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
114 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
JAMA Clinical Reviews
485 Listeners
ASCO Daily News
55 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
Oncology Today with Dr Neil Love
54 Listeners
CCO Oncology Podcast
9 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
38 Listeners